![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
134 injecting drug users (IDUs) treated at the Department of Infectious Diseases of Roslagstull Hospital, Stockholm, were tested for antibodies to human T-lymphotropic virus, types I and II, by means of 2 HTLV-I/-II peptide-based enzyme immunoassays (EIAs), followed by a whole-virus EIA. Positive EIA reactions were checked and typed by electrophoretic immunoblotting with native HTLV-I and recombinant HTLV-I and-II proteins. 10 IDUs were diagnosed as HTLV-II seropositive. All 10 were of Scandinavian descent. Thus, like HIV-1, HTLV-II infection has entered the injecting drug user population in Stockholm.